The role of pharmacogenomics in personalization of the Parkinson's disease treatment

被引：4
作者：
Redensek, Sara [1 ]
Dolzan, Vita [1 ]
机构：
[1] Univ Ljubljana, Fac Med, Inst Biochem, Pharmacogenet Lab, Vrazov Trg 2, Ljubljana 1000, Slovenia
来源：
PHARMACOGENOMICS | 2020年 / 21卷 / 14期
关键词：
clinical algorithms; clinical pharmacogenetic predictive models; data integration; individualized therapy; parkinson's disease; patient stratification; pharmacogenomics; translational medicine; CATECHOL-O-METHYLTRANSFERASE; RECEPTOR GENE POLYMORPHISMS; LEVODOPA-INDUCED DYSKINESIAS; DOPAMINE TRANSPORTER GENE; IMPULSE CONTROL DISORDERS; PEAK-DOSE DYSKINESIAS; TREATMENT RESPONSE; MOTOR COMPLICATIONS; PRECISION MEDICINE; PREDICTIVE MODELS;
D O I：
10.2217/pgs-2020-0031
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Parkinson's disease (PD) related phenotypes can vary among patients substantially, including response to dopaminergic treatment in terms of efficacy and occurrence of adverse events. Many pharmacogenetic studies have already been conducted to find genetic markers of response to dopaminergic treatment. Integration of genetic and clinical data has already resulted in construction of clinical pharmacogenetic models for prediction of adverse events. However, the results of pharmacogenetic studies are inconsistent. More comprehensive genome-wide approaches are needed to find genetic biomarkers of PD-related phenotypes to better explain the variability in response to treatment. These genetic markers should be integrated with clinical, environmental, imaging, and other omics data to build clinically useful algorithms for personalization of PD management.
引用
收藏
页码：1033 / 1043
页数：11
相关论文
共 88 条
[1]   DRD and GRIN2B polymorphisms and their association with the development of impulse control behaviour among Malaysian Parkinson's disease patients [J].
Abidin, Shahidee Zainal ;
Tan, Eng Liang ;
Chan, Soon-Choy ;
Jaafar, Ameerah ;
Lee, Alex Xuen ;
Abd Hamid, Mohd Hamdi Noor ;
Murad, Nor Azian Abdul ;
Razy, Nur Fadlina Pakarul ;
Azmin, Shahrul ;
Annuar, Azlina Ahmad ;
Lim, Shen Yang ;
Cheah, Pike-See ;
Ling, King-Hwa ;
Ibrahim, Norlinah Mohamed .
BMC NEUROLOGY, 2015, 15
[2]   Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity [J].
Acuña G. ;
Foernzler D. ;
Leong D. ;
Rabbia M. ;
Smit R. ;
Dorflinger E. ;
Gasser R. ;
Hoh J. ;
Ott J. ;
Borroni E. ;
To Z. ;
Thompson A. ;
Li J. ;
Hashimoto L. ;
Lindpaintner K. .
The Pharmacogenomics Journal, 2002, 2 (5) :327-334
[3]   Influence of genetic, biological and pharmacological factors on levodopa dose in Parkinson's disease [J].
Altmann, Vivian ;
Schumacher-Schuh, Artur F. ;
Rieck, Mariana ;
Callegari-Jacques, Sidia M. ;
Rieder, Carlos R. M. ;
Hutz, Mara H. .
PHARMACOGENOMICS, 2016, 17 (05) :481-488
[4]   OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users [J].
Becker, Matthijs L. ;
Visser, Loes E. ;
van Schaik, Ron H. N. ;
Hofman, Albert ;
Uitterlinden, Andre G. ;
Stricker, Bruno H. Ch. .
NEUROGENETICS, 2011, 12 (01) :79-82
[5]   The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease [J].
Bialecka, M ;
Drozdzik, M ;
Klodowska-Duda, G ;
Honczarenko, K ;
Gawronska-Szklarz, B ;
Opala, G ;
Stankiewicz, J .
ACTA NEUROLOGICA SCANDINAVICA, 2004, 110 (04) :260-266
[6]   The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications [J].
Bialecka, Monika ;
Kurzawski, Mateusz ;
Klodowska-Duda, Gabriela ;
Opala, Grzegorz ;
Tan, Eng-King ;
Drozdzik, Marek .
PHARMACOGENETICS AND GENOMICS, 2008, 18 (09) :815-821
[7]   Pharmacogenomics and therapeutic prospects in dementia [J].
Cacabelos, Ramon .
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2008, 258 (Suppl 1) :28-47
[8]   A review of adverse events linked to dopamine agonists in the treatment of Parkinson's disease [J].
Ceravolo, Roberto ;
Rossi, Carlo ;
Del Prete, Eleonora ;
Bonuccelli, Ubaldo .
EXPERT OPINION ON DRUG SAFETY, 2016, 15 (02) :181-198
[9]   Influence of Single Nucleotide Polymorphisms in COMT, MAO-A and BDNF Genes on Dyskinesias and Levodopa Use in Parkinson's Disease [J].
Cheshire, Perdita ;
Bertram, Kelly ;
Ling, Helen ;
O'Sullivan, Sean S. ;
Halliday, Glenda ;
McLean, Catriona ;
Bras, Jose ;
Foltynie, Tom ;
Storey, Elsdon ;
Williams, David R. .
NEURODEGENERATIVE DISEASES, 2014, 13 (01) :24-28
[10]   Adverse Events from the Treatment of Parkinson's Disease [J].
Chou, Kelvin L. .
NEUROLOGIC CLINICS, 2008, 26 (03) :S65-+
123456789